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Abstract 
Background: CIC is a transcriptional repressor inactivated by loss-of-function mutations in 
several cancer types, including gliomas, lung cancers, and gastric adenocarcinomas. CIC 
alterations and/or loss of CIC activity have been associated with poorer outcomes and more 
aggressive phenotypes across cancer types, which is consistent with the notion that CIC 
functions as a tumour suppressor across a wide range of contexts. 
Results: Using mammalian cells lacking functional CIC, we found that CIC deficiency was 
associated with chromosome segregation (CS) defects, resulting in chromosomal instability and 
aneuploidy. These CS defects were associated with transcriptional dysregulation of spindle 
assembly checkpoint and cell cycle regulators. We also identified novel CIC interacting proteins, 
including core members of the SWI/SNF complex, and showed that they cooperatively regulated 
the expression of genes involved in cell cycle regulation. Finally, we showed that loss of CIC 
and ARID1A cooperatively increased CS defects and reduced cell viability. 
Conclusions: Our study ascribes a novel role to CIC as an important regulator of the cell cycle 
and demonstrates that loss of CIC can lead to chromosomal instability and aneuploidy in human 
and murine cells through defects in CS, providing insight into the underlying mechanisms of 
CIC’s increasingly apparent role as a “pan-cancer” tumour suppressor. 
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Introduction 
Capicua (CIC) is a transcriptional repressor that is mutated or rearranged in in several 
cancer types, including undifferentiated small round cell sarcomas1 (~60% frequency), 
oligodendrogliomas2,3 (~50-80%), gastric adenocarcinomas4 (~9%), endometrial carcinomas5 
(~7%), and melanomas (~8%)6,7. CIC loss has also been implicated in prostate cancer8, lung 
cancer9, and T-cell lymphoblastic leukemia/lymphoma10,11. CIC alterations and/or loss of CIC 
activity have been associated with inferior outcomes12-15 and with aggressive phenotypes such as 
increased metastatic ability9 and resistance to MAPK inhibitors16,17, indicating that CIC likely 
functions as a tumour suppressor. Though functional studies of CIC are relatively limited in 
mammalian models, recent reports have shown that these oncogenic phenotypes appear to be 
due, at least in part, to de-repression of one or more of CIC’s known target genes – which 
include the ETS transcription factors ETV1, ETV4, and ETV5 (ETV1/4/5) – upon loss of CIC8-10.  
Chromosome instability (CIN) is a process that leads to whole- or partial-chromosome 
gains and losses and that results in aneuploidy, a cellular genetic state that is considered a 
hallmark of cancer18. Common mechanisms of aneuploid and polyploid cell formation (i.e. cells 
that contain more than two complete sets of chromosomes) include cytokinesis failure, which can 
for example be due to defects in cytokinetic proteins19, errors in chromosome segregation (CS)20, 
prolonged arrests at the spindle assembly checkpoint (SAC)21,22, DNA replication errors23, and 
cell-cell fusion24. 
Here, we describe a novel function of mammalian CIC in regulating cell cycle 
progression and CS, and show that loss of CIC is associated with CS defects and CIN, resulting 
in aneuploidy. We also find that CIC interacts with core members of the SWI/SNF complex, and 
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show that together they function to regulate the transcription of genes involved in cell cycle 
regulation and the SAC.	 
 
Results 
1. Nuclear CIC is subject to dynamic spatial and temporal re-distribution during the cell 
cycle.  
To examine the spatial dynamics of nuclear CIC, we performed immunofluorescence (IF) 
assays in two neural cell lines: an immortalized normal human astrocyte line (NHA25; Figure 1a), 
and the HOG26 line (Supplementary Figure 1). We observed that CIC was dynamically re-
distributed over the course of the cell cycle in both cell lines. As shown in Figure 1a, CIC was 
found throughout the nucleus during interphase, but appeared to be excluded from condensed 
chromosomes at metaphase and telophase. During early cytokinesis, CIC foci appeared at de-
condensing chromosomes during initiation of nuclear envelope reassembly, and increasingly 
accumulated until completion of cytokinesis (Figures 1a and Supplementary Figure 1, 
arrowheads). Upon completion of nuclear envelope assembly, CIC was observed throughout the 
nucleus.  
We confirmed this observation using an N-terminal-FLAG-tagged CIC-S construct (F-CIC-
S) introduced into an isogenic CIC knockout (CICKO) cell line derived from HEK293A27 
(hereafter referred to as HEKF-CIC-S). Ectopically expressed F-CIC-S displayed similar 
localization dynamics as endogenous CIC (Supplementary Figure 1), indicating that both CIC 
isoforms were dynamically re-localized during mitotic phases, thus raising the possibility that 
some CIC functions may be related to the cell cycle. 
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2. Loss of CIC is associated with chromosomal segregation defects in human and mouse 
cells. 
Motivated by the apparent dynamic association of CIC with chromosomes, and to explore 
the relationship between CIC function and the cell cycle, we performed IF assays on 
synchronized NHA-derived CICKO cell lines27. We synchronized the parental NHA cell line and 
two of its derivative CICKO cell lines (A2 and H9) at G2/M phase using the reversible cyclin-
dependent kinase 1 (CDK1) inhibitor RO-330628. The synchronized populations were then 
observed at 1h after drug removal (“post-release”), corresponding approximately to metaphase; 
1.5-2.5 h post-release, corresponding approximately to telophase and cytokinesis; and 3 h post-
release, corresponding approximately to G1 phase (Figure 1b). Compared to the parental CICWT 
cell line, the CICKO lines showed 2.2 - 2.5-fold increases in metaphase alignment defects (p < 
0.05) and 2 - 2.3-fold increases in CS defects at telophase/cytokinesis (p < 0.01; Methods; Figure 
1c-d). We confirmed these observations in unsynchronized HEK and two HEK-derived CICKO 
cell lines (Supplementary Figure 1). 
To determine whether CIC deficiency was also associated with CS defects in vivo, we 
examined the appearance of mitotic chromosomes at the anaphase-to-telophase stages in a 
recently reported Cic conditional knockout mouse model29. IF staining of brain sections from 
embryonic day 13.5 animals with forebrain-specific Cic knockout (Cicfl/fl;FoxG1cre/+) and from 
their heterozygous controls (Cicfll+;FoxG1cre/+) revealed that Cic-null cells in the mitotically 
active ventricular zone (VZ) displayed an increased frequency of either lagging chromosomes or 
micronuclei (average 2.5-fold increase, p < 0.0001; Figure 1e). Along with our observations 
from cultured NHA and HEK cells, these observations link CIC loss to defects in mammalian 
CS.  
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3. Loss of CIC in NHA cells is associated with copy number alterations and aneuploidy. 
CS defects such as those observed in our CICKO lines, including the presence of 
micronuclei and lagging chromosomes, have been linked to copy number alterations in daughter 
cells30-32. To determine whether evidence of copy number defects could be observed in CIC-
deficient cells, we performed single-cell genome sequencing (DLP+33) on DNA libraries from 
the parental CICWT NHA line and NHA-derived CICKO lines (A2 and H9 described above, and 
additional lines B6 and H10). Overall, the majority (73%; 1,015/1,391) of the cells we sequenced 
were triploid, thus defining the wild type ploidy status of the NHA lines (Figure 1f). An increase 
in ploidy status (i.e. tetraploidy, pentaploidy, or hexaploidy) was observed in two of the CICKO 
cell lines. 58% (163/283) of the A2 cells and 39% (113/287) of the B6 cells displayed increased 
ploidy status. We interpret these data to indicate that, in CIC mutant cells, there is an enrichment 
of cells that fail to complete cytokinesis, resulting in genome duplication that yields 6N or partial 
6N status, which then may lead to distinct cellular subpopulations with increased ploidy. We 
confirmed increases in ploidy using interphase FISH analysis to observe the arms of 
chromosomes 1 and 19. Notably, chromosomal arm ploidy ratios showed comparable 
distributions in the FISH and DLP+ data across all cell lines, indicating concordance between the 
two methods (Supplementary Figure 2). 
We next analyzed the DLP+ data to reveal the frequency and distribution of copy number 
segments in individual cells, where segments were defined as adjacent bins with identical copy 
number and neutral copy number was defined as an individual cell’s determined ploidy state 
(Methods). While the CICKO lines did not show consistent differences in the number of neutral 
segments or segments with copy number gain or loss compared to CICWT cells (Figure 1g), 
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segments with copy number loss were consistently longer in the CICKO lines compared to the 
parental NHA line (p < 0.05; Figure 1h). Thus, while the CICKO lines did not appear to incur 
more losses than the parental CICWT line, the losses occurring in CICKO cells seemed to involve 
larger chromosomal segments. Together, these observations are consistent with the notion that 
CICKO cell lines display increased CIN: specifically, an increased proportion of the genome was 
subject to copy number loss in CICKO cells compared to CICWT cells, and results indicated that 
CICKO cells may be susceptible to events that lead to ploidy alterations. 
 
4. CIC-deficient cells display delayed mitotic progression and dysregulated CCNB1 
expression.  
Given our observations that CIC loss was apparently associated with CS defects and CIN, we 
hypothesized that CIC loss might affect mitotic progression. To investigate this, we enumerated 
cells in pro-metaphase, metaphase and telophase/cytokinesis in synchronized CICWT and CICKO 
NHA lines at regular intervals following drug release (Methods). In the parental CICWT line and 
the CICKO lines (A2 and H9), similar percentages (~17% and ~14-15%, respectively) of the cells 
entered pro-metaphase 0.5 h post-release (Figure 2a). However, while 17% of the CICWT cells 
had entered metaphase 1 h post-release, only 4-6% of the CICKO cells (p < 0.05) had entered 
metaphase at that time. Similarly, while 15% of the CICWT cells had entered 
telophase/cytokinesis 2.5 h post-release, only 2-4% of the CICKO cells (p < 0.001) had entered 
telophase/cytokinesis at that time. These findings are consistent with the notion that, compared to 
CICWT cells, CICKO cells could enter pro-metaphase, but exhibited delayed progress through 
subsequent cell cycle phases. 
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The accumulation of various mitotic cyclins at specific stages throughout mitosis is critical 
for proper cell cycle progression34. Given CIC’s established function as a transcription factor, we 
hypothesized that the CS defects observed in CICKO cells may be associated with transcriptional 
dysregulation of key target genes. To measure gene expression in comparable populations of 
CICWT and CICKO cells, we performed reverse transcription followed by quantitative polymerase 
chain reaction (RT-qPCR) in unsynchronized cells (UN), synchronized cells enriched for G2/M 
(0 h post-release), and mitotic fractions collected by shake-off 0.5 h post-release (Methods), 
which contain 61-82% pro-metaphasic cells (referred to as PM; Supplementary Figure 3). 
CCNB1, which under normal conditions shows mRNA accumulation at the G2/M transition and 
through mitosis35, showed significantly reduced abundance in the CICKO lines (A2 and H9) 
compared to the parental CICWT line in G2/M and PM cells (p < 0.05; Figure 2b). The other 
cyclin genes tested did not show consistent changes in mRNA expression across both CICKO cell 
lines. We confirmed the decreased expression of CCNB1 protein and also observed increased 
expression of CCND1/2/3 proteins in synchronized and unsynchronized CICKO cells compared to 
CICWT cells (Supplementary Figure 3). Given that CCNB1 is a key regulator of mitotic 
progression, reduced CCNB1 through down-regulation of CCNB1 mRNA expression in mitotic 
CICKO cells supports the notion that loss of CIC can result in delayed entry into metaphase.  
 
5. Loss of CIC is associated with dysregulated expression of mitotic kinases and regulators 
of the spindle assembly checkpoint (SAC).  
Defects in the SAC, which acts at the pro-metaphase-to-metaphase transition, and defective 
cytokinesis have both been associated with CS defects and resulting aneuploidy36. Expression of 
mitotic kinases and genes regulating the SAC are tightly controlled, with mRNA accumulation 
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beginning in S-phase and peak mRNA levels occurring at the G2/M transition and throughout 
mitosis37. We thus hypothesized that mitotic kinases and regulators of the SAC might also 
display dysregulated expression in CICKO cells, contributing to the mitotic defects and 
aneuploidy we observed in these cells. To investigate this, we measured expression of the known 
CIC target genes ETV4/5, the SAC regulator HMGA1, the mitotic checkpoint complex kinases 
BUB1/3 and MAD2L1, and the mitotic kinases PLK1/3 and AURKA/B in CICWT and CICKO NHA 
cells. As anticipated, mRNAs corresponding to the known CIC targets ETV4 and ETV5 exhibited 
increased abundance in the CICKO cell lines compared to the CICWT line, both in synchronized 
and unsynchronized cells (p < 0.05; Figure 2c). The mRNA abundance of the SAC regulator 
HMGA1 and the mitotic kinase PLK3 were also significantly increased in both CICKO lines 
enriched for synchronized G2/M and PM cells (p < 0.05; Figure 2c). Conversely, mRNAs for the 
mitotic kinases PLK1, AURKA1, and the mitotic checkpoint complex kinases BUB1exhibited 
reduced abundance in G2/M and PM CICKO cells compared to CICWT cells (p < 0.05; Figure 2d). 
MAD2L1, AURKB, and BUB3 did not show significant differences in mRNA abundance in either 
CICKO line compared to CICWT cells (Supplementary Figure 3). Overall, these results are 
compatible with the notion that CIC loss is associated with dysregulated mRNA expression of 
some genes involved in regulating transitions in the cell cycle between pro-metaphase, 
metaphase, and cytokinesis.  
To confirm that these mRNA expression changes were a consequence of CIC loss, we 
performed a rescue experiment in which we re-introduced CIC constructs into CICKO cells and 
measured gene expression using RT-qPCR. Given that CIC exists in two isoforms – namely the 
long (CIC-L) and short (CIC-S) forms – and that we have previously shown these to have 
different patterns of distribution38, we re-introduced each isoform individually to examine their 
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effects on gene expression (A2F-CIC-S and A2F-CIC-L; Figure 3a). ETV4 and HMGA1 exhibited 
reduced expression upon re-introduction of either F-CIC-S or F-CIC-L (p < 0.001 and p < 0.01, 
respectively; Figure 3b-c), presumably as a consequence of restoration of CIC-mediated 
repressor activity. ETV5 and PLK3, on the other hand, were re-repressed only upon re-
introduction of F-CIC-S (p < 0.001 and p < 0.05, respectively). Taken together, these data are 
compatible with the notion that HMGA1 and PLK3 may be novel targets of CIC. Interestingly, 
while re-introduction of CIC-S did not affect the expression of genes that show reduced 
expression upon CIC loss in unsynchronized cells (Supplementary Figure 3), it did partially 
restore higher expression of the SAC regulators PLK1, AURKA, and BUB1 (p < 0.05) and of the 
M-phase cyclin CCNB1 (p < 0.01) in synchronized G2/M populations (Figure 3d). Only BUB1 
also showed a significant difference in expression upon re-introduction of CIC-L. While this 
could be an indirect consequence of CIC re-introduction, these results also raise the possibility 
that CIC may function as a transcriptional activator acting on these genes. Together, these 
observations are consistent with the notion that CIC-S, which is found both in the cytoplasm and 
the nucleus38, plays a significant role in the regulation of mitotic genes. The reduced expression 
of CCNB1, AURKA, BUB1, and PLK1 in CICKO but not CICWT cells is consistent with the notion 
that CIC loss leads to gene expression alterations that may delay mitotic progression, perhaps 
contributing to CIN.  
To determine whether these novel candidate target genes might be direct targets of CIC 
regulation, we identified canonical CIC binding sites39 within their promoter regions (Methods; 
Supplementary Table 1) and performed targeted chromatin immunoprecipitation (ChIP) followed 
by qPCR for these sites in unsynchronized and synchronized (0 h post-release, G2/M) cells. 
Other than the sites in the promoter regions of the known CIC target genes ETV4 and ETV5 
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(Figure 3e), none of the sites tested showed enrichment compared to a negative control region 
(NCR) and compared to CICKO cells (examples in Supplementary Figure 3), indicating that CIC 
did not directly bind to these sites. Additional primers were also designed to target regions 
lacking canonical CIC binding sites in the promoter or gene body of HMGA1 and PLK3 where 
CIC binding enrichment has previously been reported by ChIP in the HOG cell line40 (PLK3-6, 
PLK-7, HMGA1-11, and HMGA1-12, Supplementary Table 1 and Supplementary Figure 4). 
The two sites tested for PLK3 and one of the sites tested for HMGA1 showed significant 
enrichment compared to CICKO cells in the G2/M-enriched population (> 2-fold difference, p < 
0.05; Figure 3e). Taken together, these observations support the contention that PLK3 and 
HMGA1 may be direct targets of CIC regulation through interaction with non-canonical binding 
sites within their gene bodies.  
 
6. Nuclear CIC interacts with core subunits of the SWI/SNF complex. 
To gain further insight into CIC’s nuclear interaction network, we performed 
immunoprecipitation (IP) assays for endogenous CIC and N-terminal MYC-fused CIC-S (using a 
MYC antibody) in nuclear fractions purified from the HEK293 cell line (Methods; 
Supplementary Figure 5a). The immunoprecipitates were then characterized using liquid 
chromatography followed by tandem mass spectrometry (IP-MS). This yielded 53 candidate CIC 
interacting proteins that were identified in at least two of the four replicate IP-MS experiments 
(Supplementary Table 2), and the known interactors ATXN1L and ATXN241 each identified in 
one replicate (Figure 4a). To identify pathways and protein complexes that were enriched for 
candidate interactors, we performed enrichment analyses using Metascape42 and Genemania43 
and identified RNA processing, RNA localization, and chromatin organization as the most 
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significantly enriched processes (FDR < 0.05; Supplementary Table 3). Given CIC’s known 
function as a transcriptional regulator, the nine candidate interactors that were associated with 
the Gene Ontology (GO) biological process term “chromatin organization” (GO term 0006325; 
MKI67, L3MBTL3, MECP2, PBRM1, SMARCA2, SMARCC1, RUVBL1, SIN3A, and UTP3; 
Figure 4a, Supplementary Table 4) were of particular interest, along with the polymerase 
POLR2A. We thus sought to replicate these candidate interactions in nuclear fractions of the 
NHA cell line using a variation of the IP-MS technique in which 'trigger peptides44' (Methods; 
Supplementary Table 5) were used to enhance the sensitivity of the MS data for these proteins of 
interest, along with the known CIC interactor ATXN1L41 and ARID1A and ARID2, which are 
known interactors of SMARCA2, SMARCC1 and POLR2A (reviewed in references45,46). We 
were thus able to observe in NHA cells the interactions between CIC and these 14 proteins, and 
we also identified additional candidate interactors, including the SWI/SNF complex proteins 
ARID1A, ARID2, and SMARCA5 (Supplementary Table 4). Since dysregulation of core 
members of the SWI/SNF complex and proteins associated with them (e.g. SMARCA247, 
ARID1A48, and SIN3A49) has previously been linked to CS defects, we hypothesized that CIC’s 
apparent interaction with members of the SWI/SNF complex might be related to its cell cycle-
related functions. 
To further explore the relationships between CIC and SWI/SNF complex members, we 
first performed reciprocal IPs to validate the interactions between endogenous CIC and 
SMARCA2, ARID1A, SMARCC1, and POLR2A in the NHA line (Figure 4b-e), and between F-
CIC-S and SMARCA2 and ARID1A in HEK cells (Supplementary Figure 5). To identify 
common interactors between CIC and either SMARCA2 or ARID1A, we performed additional 
IP-MS experiments against ARID1A and SMARCA2 using whole-lysate preparations of NHA 
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cells (Supplementary Figure 5). These experiments identified 13 (ARID1A IP) and 11 
(SMARCA2 IP) interactors that overlapped with candidate CIC interactors (Supplementary 
Table 4). In addition to CIC, ten proteins (ARID1A, ARID2, FMR1, MTA2, L3MBTL3, 
PBRM1, SIN3A, SMARCA2, SMARCC1, and POLR2A) were recurrently identified as 
common interactors in the IP experiments (i.e. they interacted with CIC, ARIDIA, and 
SMARCA2). 
 
7. Nuclear CIC and core components of the SWI/SNF complex show similar spatial and 
temporal distribution during the cell cycle.  
Given CIC’s striking spatial redistribution over the course of the cell cycle, we reasoned that 
similar patterns of redistribution in candidate protein interactors might support a cooperative role 
in CS. Using IF co-localization assays, we observed a striking apparent co-localization of F-CIC-
S and ARID1A, SMARCA2 (Figure 4f-g), and SMARCC1 (Supplementary Figure 6) in HEKF-
CIC-S cells during early cytokinesis. These proteins also showed similar localization dynamics and 
co-localization with CIC over the course of the cell cycle. Interestingly, SIN3A did not localize 
with CIC at early cytokinesis but appeared to do so during interphase (Figure 4h). ARID2 
appeared to surround decondensing chromosomes in late telophase, but seemed to co-localize 
with CIC only later at early cytokinesis (Supplementary Figure 6b). 
To further explore the co-localization of CIC and core SWI/SNF proteins, we performed 
proximity ligation assays (PLAs50; Methods), which produces a read-out when antibodies 
targeting candidate protein interactors are within 40 nM of each other. In HEKF-CIC-S cells, PLA 
signals were detectable during interphase when anti-FLAG antibodies (marking CIC expression) 
were used with antibodies targeting ARID1A, SMARCA2, SMARCC1, or ARID2 (Figure 5a). 
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The greatest signal was observed for ARID1A, followed by SMARCA2, perhaps indicating that 
CIC interacts with these two proteins more frequently than the other SWI/SNF proteins tested. 
For all interactors tested, PLA signals were mostly observed in the nucleus during interphase and 
early cytokinesis, while during metaphase/telophase they were detected in cytoplasmic regions 
(example shown in Figure 5b for ARID1A). This is consistent with the IF co-localization 
observed for CIC, ARID1A, SMARCA2, and SMARCC1 over the course of the cell cycle, as 
described above. Our results thus indicate that CIC, ARID1A, SMARCA2, and SMARCC1 have 
similar spatial distributions in the nucleus over the course of the cell cycle, and that CIC is in 
close proximity to the SWI/SNF protein complex, with interactions peaking at early cytokinesis 
and at interphase. Our data are thus compatible with the notion that CIC functions with SWI/SNF 
complex proteins. 
 
8. Loss of CIC and ARID1A cooperatively affect chromosome segregation. 
Given that ARID1A and SMARCA2 are known to regulate CS47,48, we speculated that CIC 
might cooperate with these proteins to regulate CS. To test this hypothesis, we first performed 
siRNA knockdowns (KDs) of ARID1A and SMARCA2 in parental CICWT NHA cells and in 
isogenic CICKO lines and assessed cell viability using crystal violet assays. Interestingly, only 
ARID1A knockdown resulted in significantly lower viability in CICKO cells compared to CICWT 
cells (p < 0.0003; Figure 6a, data not shown for SMARCA2 knockdown). This decrease in 
viability was associated with an increase in metaphase alignment defects in CICKO/ARID1AKD 
cells compared to cells lacking either CIC or ARID1A (p < 0.05; Figure 6b), consistent with the 
notion that combined loss of CIC and ARID1A cooperatively increases CS defects to a degree 
sufficient to reduce cell viability.  
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We next sought to determine whether the candidate CIC target genes involved in cell cycle 
and SAC regulation that we identified in this study were co-regulated by CIC and ARID1A. In 
CICWT cells, ARID1A knockdown was associated with increased expression of the known CIC 
targets ETV4 and ETV5 (p < 0.05 and p < 0.00001, respectively; Figure 6c-d). Interestingly, 
combined loss of CIC and ARID1A was associated with a significant increase in the expression 
of ETV5 (p < 0.0001; Figure 6d) and PLK3 (p < 0.001; Figure 6e) and lower expression of 
CCNB1 (p < 0.05; Figure 6f) relative to CIC loss alone, indicating that the expression of these 
genes is cooperatively regulated by CIC and ARID1A. The mitotic regulator HMGA1 (Figure 
6g) only showed increased expression in CICKO cells and did not show a further increase in 
expression upon ARID1A knockdown, indicating that its expression is not regulated in 
cooperative fashion. 
Taken together, these results indicate that CIC can interact with members of the 
SWI/SNF complex and can cooperatively regulate genes involved in CS; furthermore, ARID1A 
knockdown appears to cooperate with CIC deficiency to decrease cell viability, perhaps through 
an increase in CS defects.  
 
Discussion 
In this study, we use human cells and a mouse model to describe a novel role for 
mammalian CIC in regulating mitotic progression and chromosome stability. We show that CIC 
is dynamically re-distributed over the course of the cell cycle, and that its loss is associated with 
defects in metaphase alignment and CS both in vitro and in vivo. Using DLP+ and interphase 
FISH analysis of NHA-derived CICKO cells, we show that these defects are associated with CIN 
and alterations in ploidy. We propose that these phenotypes result, at least in part, from the 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/533323doi: bioRxiv preprint first posted online Jan. 29, 2019; 
16	
	
transcriptional dysregulation of genes involved in cell cycle regulation, which we observed upon 
loss of CIC (Figure 7). For instance, overexpression of HMGA151,52 or PLK353, both of which 
our results supported as novel targets of CIC transcriptional repression, has been shown to 
induce mitotic arrest and apoptosis. Meanwhile, a decrease in CCNB1 levels, which we also 
observed in response to CIC loss, has been shown to contribute to polyploidization in response to 
DNA damage54.  
We also show that CIC interacts with core members of the SWI/SNF complex, namely 
ARID1A, SMARCA2, and SMARCC1. This raises the intriguing possibility that CIC might 
function as a member of the SWI/SNF complex. Of these, ARID1A knockdown was found to 
cooperatively increase mitotic defects and reduce cell viability in CICKO cells. We show that CIC 
and ARID1A cooperatively regulate the expression of genes involved in mitotic regulation, 
implying that this activity may be at least partially responsible for the defects observed in cells 
lacking both functional proteins (Figure 7). The ARID1A and CIC genes are located on 
chromosomal arms 1p36.11 and 19q13.2, respectively, and are thus both subject to loss of 
heterozygosity (LOH) in 1p/19q co-deleted LGGs2,3. Although CIC is frequently mutated in 
these tumours and ARID1A mutations are common in other cancer types55,56, only 0.02% (3/169) 
of 1p/19q co-deleted LGG cases from The Cancer Genome Atlas (TCGA) harbour mutations in 
these two genes6,7,57. This observation, together with our own results, indicates that the combined 
inactivation of CIC and ARID1A is associated with decreased cellular viability, and may not be 
compatible with proliferation of cancer cells. If the response we observed when both protein 
products are lost can be recapitulated in tumour contexts, such a synthetic lethal relationship 
could possibly be exploited in the context of therapy for tumours lacking either functional CIC or 
ARID1A. 
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Conclusions 
Our study establishes a novel role for CIC in cell cycle regulation and accurate CS and 
shows that loss of CIC is associated with a disruption in these processes, resulting in aneuploidy. 
We present evidence that these consequences are mediated through the transcriptional 
dysregulation of genes involved in cell cycle regulation and the SAC, including CCNB1 and the 
proposed novel CIC targets HMGA1 and PLK3. We also uncovered a previously unappreciated 
relationship between CIC and the SWI/SNF complex comprised of cell cycle-dependent 
interactions, showing that they function together to regulate gene expression and ensure proper 
CS. These novel roles ascribed to CIC establish it as an important regulator of the cell cycle and 
provide a plausible explanation for its role as a tumour suppressor across a wide range of cancer 
contexts.  
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Figure 1: Loss of CIC is associated with chromosomal segregation defects and CIN 
a. IF staining of endogenous CIC and the nuclear envelope protein NUP62 in the parental NHA 
line. CIC shows a punctate localization pattern (arrowheads) throughout the decondensing 
nucleus. Scale bars: 10 µm and 5 µm (zoomed image). 
b. Time points at which cells were collected following synchronization with RO-3306. 
c. Synchronized CICKO cells show defects in metaphase alignment and a lagging chromosome at 
telophase (arrowhead). Left: DAPI staining alone. Scale bars: 10 µm. 
d. Top: example images of cells with normal or defective metaphase or cytokinesis.  Bottom: 
proportions of cells assigned to each category. Bars represent the mean from three independent 
experiments and error bars indicate the standard error of the mean (s.e.m). *p < 0.05, **p < 0.01 
(two-sided Student’s t-test comparing combined minor and severe defects). 
e. Left: mitotically active (boxed) VZ region from a E13.5 Cicfl/+;FoxG1cre/+ mouse forebrain 
and representative images of lagging chromosomes and micronuclei (arrowheads, bottom left 
and right, respectively) in Cicfl/fl;FoxG1cre/+ mice. Right: proportions of cells with defective 
anaphase/telophase. Bars represent the mean from four animals for each genotype and error bars 
indicate s.e.m (n = 186 total for Cicfl/+;FoxG1cre/+ mice and 180 for Cicfl/fl;FoxG1cre/+ mice). 
****p < 0.0001 (Student’s t-test). Scale bars: 100 µm (top left) and 10 µm. 
f. Number of cells with indicated ploidy status profiled by DLP+. 
g-h. Tukey boxplots of segment counts (g) and mean length of segments (h) for indicated copy 
number statuses. *p < 5x10-2, **p < 5x10-10, ***p < 5x10-20 (Wilcoxon test with Bonferroni 
correction for each copy number status). 
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Figure 2. Loss of CIC is associated with transcriptional dysregulation of cell cycle 
regulators and members of the SAC complex. 
a. Proportion of CICWT (NHA) and CICKO (A2 and H9) cells classified as being in pro-
metaphase, metaphase, or telophase/cytokinesis based on DAPI and α-tubulin staining (see 
examples in Figure 1a and c) at six time points following RO-3306 release. Bars represent the 
mean of at least 747 cells from three independent experiments, and error bars represent s.e.m. *p 
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< 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA with Holm-Sidak’s multiple comparison 
test for each time point). 
b-d. mRNA expression of CCNB1, CCND1, CCNE2, and CCNA2 (b), the known CIC targets 
ETV4 and ETV5 and the mitotic regulators HMGA1 and PLK3 (c), and the mitotic kinases PLK1, 
AURKA1, and BUB1 (d) in unsynchronized cells (UN), synchronized cells at G2/M (0 h post-
release) and pro-metaphasic (PM) cells obtained by mitotic shake-off at 0.5 h post-release, as 
measured by RT-qPCR. Expression is shown as fold-changes relative to the unsynchronized 
NHA cells. Error bars indicate s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA 
with Holm-Sidak’s multiple comparison test for each time point).	  
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Figure 3. CIC regulates the expression of mitotic regulators. 
a. Western blot showing expression of endogenous CIC-L and CIC-S in the parental NHA line 
(CICWT), CICKO lines (A2 and H9), and A2 cells ectopically expressing an empty vector (V), F-
CIC-S, or F-CIC-L, detected using antibodies against CIC (top) or FLAG (bottom).  
b-d. Relative expression of the known CIC targets ETV4 and ETV5 (b) and mitotic regulators 
showing increased (c) or decreased (d) expression in CICKO cells compared to CICWT cells. Gene 
expression in A2 cells expressing F-CIC-S or F-CIC-L was measured in independent 
experiments. Panels b and c represent measurements made in unsynchronized cells, while panel 
d represents measurements made in synchronized cells 0.5 h post-release. Expression is shown as 
fold-changes relative to the NHA cells. Bars represent the mean from three independent 
experiments and error bars indicate s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
(two-sided Student’s t-test). 
e. Enrichment of CIC binding at indicated sites relative to the NCR, as measured by ChIP-qPCR 
for CIC in CICWT (NHA) and CICKO (A2) cell lines in unsynchronized (UN) and synchronized 
G2/M cells. Bars represent the mean from three independent experiments and error bars 
represent sem. *p < 0.05 (two-sided Student’s t-test).	  
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Figure 4: Nuclear CIC interacts with members of the SWI/SNF complex. 
a. Interaction map showing select CIC interactors identified by IP-MS assays, namely the nine 
candidate CIC interactors that belong to the “Chromatin organization” GO term (blue), POLR2A 
(white), a known interactor of SMARCA2 and SMARCC1, and known CIC interactors (pink).  
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b-e. Reciprocal IPs confirming the interaction between CIC and ARID1A (b), SMARCA2 (c), 
SMARCC1 (d), and POLR2A (e) in the parental NHA cell line, visualized by western blot. CIC-
L and CIC-S bands are marked with arrowheads. 
f-h. Localization of F-CIC-S (FLAG, red), ARID1A (f) SMARCA2 (g), and SIN3A (h, all 
green) in HEKF-CIC-S cells at indicated phases of the cell cycle, detected by IF. DNA was stained 
with DAPI (blue). Arrowheads indicate co-localization of CIC and the relevant interactor at early 
cytokinesis (yellow foci). Scale bars: 10µm and 5µm (zoomed image in g).	  
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Figure 5: PLA assays indicate CIC and SWI/SNF complex proteins are in close proximity.  
a. Top: representative PLAs using antibodies against FLAG and ARID1A, SMARCA2, 
SMARCC1, or ARID2 in HEK-derived CICKO cells expressing F-CIC-S (HEKF-CIC-S, top) or an 
empty vector (HEKF-Vec, bottom). DNA was visualized using DAPI staining (blue), and PLA 
spots indicating close proximity of the proteins assayed (< 40nm) are visualized in red. Bottom: 
quantifications of PLA spots per nuclear region. The line represents the median of at least 532 
cells, the hinges represent the first and third quartiles, and the error bars represent the total range. 
Scale bars: 10µm.  ****p < 0.0001 (Welch’s t-test). 
b. Top: representative PLAs using antibodies against FLAG and ARID1A in HEKF-CIC-S (top) 
and HEKF-Vec (bottom) cells. Bottom: quantification of PLA spots in nuclear (Nuc) and 
cytoplasmic (Cyto) regions in cells at metaphase and early cytokinesis. The nuclear envelope 
was visualized by IF staining of NUP62 (green). In the box and whiskers plots, the hinges 
represent the first and third quartiles, the line represents the median, and the error bars represent 
range. Scale bars: 10µm. ****p < 0.0001 (one-way ANOVA with Holm-Sidak’s multiple 
comparison).	  
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Figure 6. Concurrent loss of CIC and ARID1A cooperatively increases mitotic defects and 
decreases cell viability. 
a. Crystal violet cell viability assay in NHA (CICWT) and A2 and H9 (CICKO) cells treated with a 
non-targeting siRNA (control, scramble) or one of two independent siRNAs against ARID1A 
(KD1 and KD2, KD1 is shown in the representative image). Proliferation indices were generated 
relative to their respective controls, and quantifications from three independent experiments are 
shown below. Bars represent the mean and error bars indicate s.e.m. *p < 0.05, **p < 0.01 (one-
way ANOVA with Holm-Sidak’s multiple comparison). 
b. Top: representative IF images of NHA (CICWT) and A2 (CICKO) cells treated with a non-
targeting siRNA (negative control, NC1) or an siRNA against ARID1A (ARID1AKD1). DNA 
(DAPI, blue) and expression of β-tubulin (green) were visualized at metaphase and 
telophase/cytokinesis. Arrowheads indicate multipolar chromosome alignments at metaphase and 
lagging chromosomes at cytokinesis in CICKO cells. Bottom: quantification of defects. Bars 
represent the mean across three independent experiments and error bars indicate s.e.m. Scale 
bars: 10µm. **p < 0.01 (one-way ANOVA with Holm-Sidak’s multiple comparison). 
c-g. Relative expression of select genes in NHA (CICWT) and A2 (CICKO) cells treated with a 
non-targeting control siRNA (scr) or a siRNA targeting ARID1A (KD2), as measured by RT-
qPCR. Expression is shown as fold-changes relative to the NHA cells treated with the non-
targeting control siRNA. The known CIC targets ETV4 (c) and ETV5 (d) are shown, as are the 
mitotic regulators PLK3 (e), CCNB1 (f), and HMGA1 (g). *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 (t-tests with Holm-Sidak’s multiple correction). 
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Figure 7. Working model: CIC functions as a tumour suppressor through regulation of 
CIN and ploidy alteration. 
a. When CIC is present, it interacts with members of the SWI/SNF complex to regulate the 
expression of target genes, including mitotic regulators 
b. In the absence of CIC, the known targets of CIC transcriptional regulation ETV4 and ETV5, as 
well as HMGA1 and PLK3, which our results indicate are novel direct targets of CIC regulation, 
show elevated expression. Mitotic regulators, including AURKA, BUB1, and PLK1 also show 
dysregulated expression that may be an indirect consequence of CIC loss. Together, these 
transcriptional changes appear to contribute to defective mitosis, CIN, and aneuploidy, which are 
observed at higher frequency in CICKO cells.  
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